久久久久久亚洲精品a片成人,一二三四在线观看免费高清视频,色婷婷五月在线精品视频,国产色视频自在线观看

Recently, Quarkmed successfully completed its Series A financing, securing tens of millions of RMB in funding led by Tai Kun Fund, with follow-on investments from Mint Angel Fund and Guoshun Jianheng Fund. Against the backdrop of global economic downturn and slowing pharmaceutical investments, Quarkmed defies the trend and further demonstrates its comprehensive strength in clinical research services.

Radioactive drugs lead the new trend and solidify Quarkmed's clinical service foundation.

Radioactive drugs are leading a revolution in the medical field, achieving true precision medicine. By 2030, the global radioactive drug market is expected to exceed $ 20 billion, with the Chinese market projected to grow tenfold in the next decade. Since establishing radioactive drug research and development services as its strategic direction in 2018, Quarkmed has rapidly achieved a series of milestone results in this field, including successfully completing and approving the Phase III clinical trial of China's first new product for cancer bone metastasis detection as a CRO. Through accumulated expertise, Quarkmed has established a comprehensive and efficient service system for radioactive drug clinical research.

1+1>2: Radiopharmaceutical Clinical Capabilities Drive Multidisciplinary Expansion

Not only does Quarkmed hold leading advantages in the field of radiopharmaceuticals, but the company has also expanded its service philosophy cultivated in this field to other key areas, including the Central Nervous System and Gene and Cell Therapy, leveraging its accumulated technology and experience. The high-threshold technology, clinical execution capabilities, and program design experience in radiopharmaceuticals have equally excelled in these emerging fields, achieving a synergistic effect of "1+1＞2".

Multi-center clinical service capabilities reach new heights

Quarkmed CEO Mr. Yuan Dawei stated: "This round of financing will not only drive Quarkmed's further development in the field of radiopharmaceuticals but also empower the company's overall improvement in multi-center clinical service capabilities. Based on our existing efficient team and comprehensive service chain, we will provide more precise and professional clinical solutions. Quarkmed's vision is to achieve high-quality professional services through deep cultivation and focus on niche markets, helping clients achieve outstanding research results and driving the development of the entire industry."

Relying on its core competencies accumulated in focused areas, Quarkmed has comprehensively enhanced the maturity and professionalism of its services. The company's established efficient clinical research service system covering the entire process not only improves the efficiency and quality of clinical trials but also saves clients considerable time and resources. Looking ahead, Quarkmed will continue to improve its radioactive drug service chain and comprehensive clinical research capabilities, aiming to provide more comprehensive and higher-quality services and become a highly reputable CRO partner.